Thus, responsiveness to ICI therapy is correlated to the presence of pre-existing anti-tumour CD8 T-cells that express PD-1 and are thus shackled by PD-L1/2 expression on tumour cells [70, 71]. The gene discussed is CD8A; the disease is neoplasm.